Bausch Health Companies Inc. (BHC) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Bausch Health is a global specialty pharmaceutical and medical device company operating through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb (B+L). The Company continues to pursue the separation of its B+L eye health business, currently holding approximately 87% of B+L's outstanding shares. The quarter was significantly impacted by the failure of Phase 3 clinical trials for the Company's rifaximin soluble solid dispersion formulation, leading to a material goodwill impairment.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $2,524 | $2,259 |
| Operating (Loss) Income | $(950) | $276 |
| Net Loss (Attributable to BHC) | $(1,423) | $(58) |
| Loss Per Share (Basic & Diluted) | $(3.82) | $(0.16) |
| Net Cash Provided by Operating Activities | $230 | $211 |
| Cash and Cash Equivalents (Total) | $1,312 | $1,157 |
| Total Debt Obligations (Principal) | $20,212 | $20,232 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12% to $2.524 billion, driven by improved net realized pricing ($229M), favorable foreign currency impacts ($71M), and acquisitions ($33M). This was partially offset by lower volumes ($64M) due to the strategic exit of certain high-rebate channels in the Salix and Diversified segments.
- Goodwill Impairment: A non-cash goodwill impairment charge of $1,426 million was recorded for the Salix reporting unit. This followed the failure of two Phase 3 clinical trials (RED-C) for the rifaximin soluble solid dispersion formulation to meet primary endpoints in January 2026.
- Operating Loss: The Company reported an operating loss of $950 million compared to operating income of $276 million in Q1 2025. The decline is primarily attributable to the goodwill impairment and increased interest expense ($72M increase) due to higher effective rates on refinanced debt.
- Segment Performance:
- Salix: Revenue up 18% ($639M); Profit up 26% ($468M) despite the impairment charge (which is excluded from segment profit).
- Solta Medical: Revenue up 51% ($171M) driven by the Shibo Zhenmei acquisition and volume growth.
- Bausch + Lomb: Revenue up 9% ($1.244B); Profit up 54% ($277M) driven by pricing and volume growth.
- Diversified: Revenue down 10% ($185M) due to volume declines in Neuroscience and Dermatology.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Trial Failure: The failure of the RED-C trials for rifaximin SSD is a significant negative development for the Salix pipeline, directly triggering the $1.426 billion impairment.
- Debt Refinancing: The Company executed significant refinancing in late 2025 and early 2026, including the "April 2025 Refinancing Transactions" and "B+L January 2026 Credit Facility Amendment," extending maturities and managing leverage. Interest expense increased as a result of higher effective rates on new debt.
- B+L Separation: The planned separation of Bausch + Lomb remains contingent on achieving targeted debt leverage ratios. The Company continues to evaluate monetization options for its B+L holdings.
- Legal Proceedings:
- Xifaxan Litigation: Ongoing Paragraph IV litigation with generic manufacturers (Norwich, Amneal, Hetero). The FDA granted tentative approval to Norwich's ANDA but remains enjoined from final approval until October 2029 pending litigation outcomes.
- Antitrust: The Company is defending against multidistrict antitrust litigation regarding generic pricing. A Canadian antitrust action was dismissed in February 2026.
- Securities Litigation: A U.S. securities class action (Kelk) was dismissed with prejudice in November 2025; plaintiffs have appealed.
- IRA Impact: Xifaxan was selected for the Inflation Reduction Act drug price negotiation program. The negotiated price is expected to take effect in 2027, with revenue impact anticipated to be concentrated in that year.
- Tariffs: The Company is evaluating the impact of new U.S. tariffs on pharmaceuticals announced in April 2026, though no material impact is currently expected.
Investor Verification Checklist
- Salix Pipeline Viability: Assess the long-term impact of the failed RED-C trials on the Salix segment's future cash flows and the remaining goodwill balance ($1.733 billion).
- Debt Service Capacity: Verify the Company's ability to meet significant debt maturities ($3.765 billion in 2028, $4.123 billion in 2030) and high interest payments ($1.422 billion expected for remainder of 2026) given the current operating loss.
- B+L Separation Timeline: Monitor progress on debt reduction targets required to finalize the B+L spin-off and the potential for monetization of the 87% B+L stake.
- Xifaxan Generic Defense: Track the status of the Norwich and Amneal litigation, as a loss could accelerate generic entry and revenue erosion for the Company's top product.
- Channel Exit Impact: Evaluate the long-term sustainability of revenue growth following the exit of high-rebate channels in Salix and Diversified segments.